SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: A systematic review

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) is a common comorbidity with type 2 diabetes. The existing therapeutic options for NAFLD are not adequate. Hypocaloric diet and exercise is the cornerstone of therapy in NAFLD. Pioglitazone is the only drug recommended in diabetes patients with b...

Descripción completa

Detalles Bibliográficos
Autores principales: Raj, Henith, Durgia, Harsh, Palui, Rajan, Kamalanathan, Sadishkumar, Selvarajan, Sandhiya, Kar, Sitanshu Sekhar, Sahoo, Jayaprakash
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2019
Materias:
Systematic Reviews
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379733/
https://www.ncbi.nlm.nih.gov/pubmed/30788048
http://dx.doi.org/10.4239/wjd.v10.i2.114

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6379733/
https://www.ncbi.nlm.nih.gov/pubmed/30788048
http://dx.doi.org/10.4239/wjd.v10.i2.114

Ejemplares similares